Cover Image

Granulocyte–colony stimulating factor plus plerixafor in patients with β-thalassemia major results in the effective mobilization of primitive CD34+ cells with specific gene expression profile

Elena Baiamonte, Rita Barone, Flavia Contino, Rosalia Di Stefano, Anna Marfia, Aldo Filosa, Emanuela D'Angelo, Salvatore Feo, Santina Acuto, Aurelio Maggio
  • Elena Baiamonte
    Campus of Hematology F. and P. Cutino, Villa Sofia-Cervello Hospital, Palermo, Italy | elenabaiamonte77@gmail.com
  • Rita Barone
    Campus of Hematology F. and P. Cutino, Villa Sofia-Cervello Hospital, Palermo, Italy
  • Flavia Contino
    Department of Biological, Chemical and Pharmaceutical Sciences and Technologies and ATeN Center, University of Palermo, Italy
  • Rosalia Di Stefano
    Campus of Hematology F. and P. Cutino, Villa Sofia-Cervello Hospital, Palermo, Italy
  • Anna Marfia
    Division of Hematology, Villa Sofia-Cervello Hospital, Palermo, Italy
  • Aldo Filosa
    Center for Anemias, A. Cardarelli Hospital, Napoli, Italy
  • Emanuela D'Angelo
    Pediatric Clinic De Marchi, Policlinico Hospital, Milan, Italy
  • Salvatore Feo
    Department of Biological, Chemical and Pharmaceutical Sciences and Technologies and ATeN Center, University of Palermo, Italy
  • Santina Acuto
    Campus of Hematology F. and P. Cutino, Villa Sofia-Cervello Hospital, Palermo, Italy
  • Aurelio Maggio
    Campus of Hematology F. and P. Cutino, Villa Sofia-Cervello Hospital, Palermo, Italy

Abstract

Successful gene therapy for β-thalassemia requires optimal numbers of autologous gene-transduced hematopoietic stem and progenitor cells (HSPCs) with high repopulating capacity. Previous studies suggested superior mobilization in these patients by the combination of granulocyte–colony stimulating factor (G-CSF) plus plerixafor over single agents. We mobilized four adult patients using G-CSF+plerixafor to assess the intra-individual variation of the circulating CD34+ cells number and subtypes preand post-plerixafor administration. The procedure was well-tolerated and the target cell dose of ≥8×106 CD34+ cells/kg was achieved in three of them with one apheresis procedure. The addition of plerixafor unanimously increased the number of circulating CD34+ cells, and the frequency of the most primitive CD34+ subtypes: CD34+/38- and CD34+/133+/38- as well as the in vitro clonogenic potency. Microarray analyses of CD34+ cells purified from the leukapheresis of one patient mobilized twice, with G-CSF and with G-CSF+plerixafor, highlighted in G-CSF+plerixafor-mobilized CD34+ cells, higher levels of expression genes involved in HSPC motility, homing, and cell cycles. In conclusion, G-CSF+plerixafor in β-thalassemia patients mobilizes optimal numbers of HSPCs with characteristics that suggest high capacity of engraftment after transplantation.

 

β地中海贫血的成功基因治疗需要最佳数量具有较高再生能力的自体基因转导的造血干细胞和祖细胞(HSPC)。之前的研究表明,与单药相比,通过组合粒细胞集落刺激因子(G-CSF)加普乐沙福在这些患者中有出色的动员作用。我们使用G-CSF+普乐沙福对四例成年患者进行了动员,以评估服用普乐沙福之前和之后的循环CD34+细胞数量和亚型的个体内差异。这种方式的耐受性好,其中的三例患者仅通过一次分离技术即获得≥8×106 CD34+细胞/kg的细胞采集目标。加用普乐沙福毫无例外地增加了循环CD34+细胞的数量和最原始CD34+亚型(CD34+/38-和CD34+/133+/38+)的频率以及体外克隆效力。一例血细胞分离术中纯化的CD34+细胞微阵列分析(患者使用G-CSF和G-CSF+普乐沙福动员两次)强调,在G-CSF+普乐沙福动员的CD34+细胞中,有更高水平的表达基因牵涉到HSPC运动性、归巢和细胞周期。总之,G-CSF+普乐沙福在β地中海贫血病患者中可以动员最优数量的HSPC,具有移植后的移植成活率高的特征。

Keywords

β-thalassemia; CD34+ cells expression profiling; G-CSF+plerixafor mobilization; gene therapy.

Full Text:

PDF
Supplementary Table
Submitted: 2016-11-15 12:07:15
Published: 2017-05-26 12:04:45
Search for citations in Google Scholar
Related articles: Google Scholar
Abstract views:
316

Views:
PDF
215
Supplementary Table
9

Article Metrics

Metrics Loading ...

Metrics powered by PLOS ALM


Copyright (c) 2017 Elena Baiamonte, Rita Barone, Flavia Contino, Rosalia Di Stefano, Anna Marfia, Aldo Filosa, Emanuela D'Angelo, Salvatore Feo, Santina Acuto, Aurelio Maggio

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
 
© PAGEPress 2008-2017     -     PAGEPress is a registered trademark property of PAGEPress srl, Italy.     -     VAT: IT02125780185